nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—CYP1A2—Omeprazole—Barrett's esophagus	0.314	1	CbGbCtD
Rasagiline—Oesophageal ulcer—Esomeprazole—Barrett's esophagus	0.00982	0.0172	CcSEcCtD
Rasagiline—Oesophageal ulcer—Omeprazole—Barrett's esophagus	0.00982	0.0172	CcSEcCtD
Rasagiline—Dysaesthesia—Omeprazole—Barrett's esophagus	0.00829	0.0145	CcSEcCtD
Rasagiline—Dysaesthesia—Esomeprazole—Barrett's esophagus	0.00829	0.0145	CcSEcCtD
Rasagiline—BCL2—epithelium—Barrett's esophagus	0.00779	0.306	CbGeAlD
Rasagiline—Hernia—Omeprazole—Barrett's esophagus	0.00764	0.0134	CcSEcCtD
Rasagiline—Hernia—Esomeprazole—Barrett's esophagus	0.00764	0.0134	CcSEcCtD
Rasagiline—BCL2—smooth muscle tissue—Barrett's esophagus	0.0075	0.295	CbGeAlD
Rasagiline—Tongue oedema—Esomeprazole—Barrett's esophagus	0.00639	0.0112	CcSEcCtD
Rasagiline—Tongue oedema—Omeprazole—Barrett's esophagus	0.00639	0.0112	CcSEcCtD
Rasagiline—BCL2—digestive system—Barrett's esophagus	0.00592	0.233	CbGeAlD
Rasagiline—Polyp—Omeprazole—Barrett's esophagus	0.00589	0.0103	CcSEcCtD
Rasagiline—Polyp—Esomeprazole—Barrett's esophagus	0.00589	0.0103	CcSEcCtD
Rasagiline—Laryngeal oedema—Esomeprazole—Barrett's esophagus	0.00558	0.0098	CcSEcCtD
Rasagiline—Laryngeal oedema—Omeprazole—Barrett's esophagus	0.00558	0.0098	CcSEcCtD
Rasagiline—Parosmia—Esomeprazole—Barrett's esophagus	0.00552	0.0097	CcSEcCtD
Rasagiline—Parosmia—Omeprazole—Barrett's esophagus	0.00552	0.0097	CcSEcCtD
Rasagiline—Cyst—Omeprazole—Barrett's esophagus	0.00536	0.00941	CcSEcCtD
Rasagiline—Cyst—Esomeprazole—Barrett's esophagus	0.00536	0.00941	CcSEcCtD
Rasagiline—Apathy—Esomeprazole—Barrett's esophagus	0.00502	0.00881	CcSEcCtD
Rasagiline—Apathy—Omeprazole—Barrett's esophagus	0.00502	0.00881	CcSEcCtD
Rasagiline—Flat affect—Esomeprazole—Barrett's esophagus	0.00497	0.00873	CcSEcCtD
Rasagiline—Flat affect—Omeprazole—Barrett's esophagus	0.00497	0.00873	CcSEcCtD
Rasagiline—Tongue disorder—Esomeprazole—Barrett's esophagus	0.00493	0.00865	CcSEcCtD
Rasagiline—Tongue disorder—Omeprazole—Barrett's esophagus	0.00493	0.00865	CcSEcCtD
Rasagiline—Albuminuria—Omeprazole—Barrett's esophagus	0.0048	0.00843	CcSEcCtD
Rasagiline—Albuminuria—Esomeprazole—Barrett's esophagus	0.0048	0.00843	CcSEcCtD
Rasagiline—Scotoma—Esomeprazole—Barrett's esophagus	0.00472	0.00828	CcSEcCtD
Rasagiline—Scotoma—Omeprazole—Barrett's esophagus	0.00472	0.00828	CcSEcCtD
Rasagiline—BCL2—Apoptosis—MCL1—Barrett's esophagus	0.00444	0.049	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP26A1—Barrett's esophagus	0.00444	0.0489	CbGpPWpGaD
Rasagiline—Ageusia—Esomeprazole—Barrett's esophagus	0.00442	0.00776	CcSEcCtD
Rasagiline—Ageusia—Omeprazole—Barrett's esophagus	0.00442	0.00776	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—MCL1—Barrett's esophagus	0.00417	0.0459	CbGpPWpGaD
Rasagiline—Accidental injury—Esomeprazole—Barrett's esophagus	0.00405	0.00711	CcSEcCtD
Rasagiline—Accidental injury—Omeprazole—Barrett's esophagus	0.00405	0.00711	CcSEcCtD
Rasagiline—Arthropathy—Esomeprazole—Barrett's esophagus	0.00394	0.00692	CcSEcCtD
Rasagiline—Dysmenorrhoea—Omeprazole—Barrett's esophagus	0.00394	0.00692	CcSEcCtD
Rasagiline—Arthropathy—Omeprazole—Barrett's esophagus	0.00394	0.00692	CcSEcCtD
Rasagiline—Dysmenorrhoea—Esomeprazole—Barrett's esophagus	0.00394	0.00692	CcSEcCtD
Rasagiline—Hypocalcaemia—Omeprazole—Barrett's esophagus	0.00391	0.00687	CcSEcCtD
Rasagiline—Hypocalcaemia—Esomeprazole—Barrett's esophagus	0.00391	0.00687	CcSEcCtD
Rasagiline—BCL2—TP53 Network—CDKN2A—Barrett's esophagus	0.00369	0.0407	CbGpPWpGaD
Rasagiline—Vaginal inflammation—Omeprazole—Barrett's esophagus	0.00358	0.00629	CcSEcCtD
Rasagiline—Blood pressure increased—Esomeprazole—Barrett's esophagus	0.00358	0.00629	CcSEcCtD
Rasagiline—Vaginal inflammation—Esomeprazole—Barrett's esophagus	0.00358	0.00629	CcSEcCtD
Rasagiline—Blood pressure increased—Omeprazole—Barrett's esophagus	0.00358	0.00629	CcSEcCtD
Rasagiline—Melaena—Omeprazole—Barrett's esophagus	0.0035	0.00614	CcSEcCtD
Rasagiline—Melaena—Esomeprazole—Barrett's esophagus	0.0035	0.00614	CcSEcCtD
Rasagiline—BCL2—Overview of nanoparticle effects—PTGS2—Barrett's esophagus	0.00345	0.0381	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—PPARG—Barrett's esophagus	0.00341	0.0377	CbGpPWpGaD
Rasagiline—BCL2—Inflammasomes—RELA—Barrett's esophagus	0.00341	0.0376	CbGpPWpGaD
Rasagiline—Vaginal infection—Esomeprazole—Barrett's esophagus	0.00338	0.00594	CcSEcCtD
Rasagiline—Vaginal infection—Omeprazole—Barrett's esophagus	0.00338	0.00594	CcSEcCtD
Rasagiline—BCL2—Overview of nanoparticle effects—CXCL8—Barrett's esophagus	0.00335	0.0369	CbGpPWpGaD
Rasagiline—Oesophagitis—Omeprazole—Barrett's esophagus	0.00327	0.00575	CcSEcCtD
Rasagiline—Oesophagitis—Esomeprazole—Barrett's esophagus	0.00327	0.00575	CcSEcCtD
Rasagiline—Neoplasm—Omeprazole—Barrett's esophagus	0.00324	0.00569	CcSEcCtD
Rasagiline—Neoplasm—Esomeprazole—Barrett's esophagus	0.00324	0.00569	CcSEcCtD
Rasagiline—Mouth ulceration—Omeprazole—Barrett's esophagus	0.00324	0.00569	CcSEcCtD
Rasagiline—Urine output increased—Esomeprazole—Barrett's esophagus	0.00324	0.00569	CcSEcCtD
Rasagiline—Urine output increased—Omeprazole—Barrett's esophagus	0.00324	0.00569	CcSEcCtD
Rasagiline—Mouth ulceration—Esomeprazole—Barrett's esophagus	0.00324	0.00569	CcSEcCtD
Rasagiline—Gynaecomastia—Esomeprazole—Barrett's esophagus	0.00321	0.00563	CcSEcCtD
Rasagiline—Gynaecomastia—Omeprazole—Barrett's esophagus	0.00321	0.00563	CcSEcCtD
Rasagiline—Hypertonia—Esomeprazole—Barrett's esophagus	0.00314	0.00551	CcSEcCtD
Rasagiline—Hypertonia—Omeprazole—Barrett's esophagus	0.00314	0.00551	CcSEcCtD
Rasagiline—Polyuria—Esomeprazole—Barrett's esophagus	0.00296	0.0052	CcSEcCtD
Rasagiline—Polyuria—Omeprazole—Barrett's esophagus	0.00296	0.0052	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—MCL1—Barrett's esophagus	0.00295	0.0326	CbGpPWpGaD
Rasagiline—Gastroenteritis—Esomeprazole—Barrett's esophagus	0.00293	0.00515	CcSEcCtD
Rasagiline—Gastroenteritis—Omeprazole—Barrett's esophagus	0.00293	0.00515	CcSEcCtD
Rasagiline—Vascular purpura—Omeprazole—Barrett's esophagus	0.00291	0.0051	CcSEcCtD
Rasagiline—Vascular purpura—Esomeprazole—Barrett's esophagus	0.00291	0.0051	CcSEcCtD
Rasagiline—Injury—Omeprazole—Barrett's esophagus	0.00283	0.00497	CcSEcCtD
Rasagiline—Injury—Esomeprazole—Barrett's esophagus	0.00283	0.00497	CcSEcCtD
Rasagiline—Purpura—Esomeprazole—Barrett's esophagus	0.0027	0.00474	CcSEcCtD
Rasagiline—Purpura—Omeprazole—Barrett's esophagus	0.0027	0.00474	CcSEcCtD
Rasagiline—Arthritis—Omeprazole—Barrett's esophagus	0.00268	0.0047	CcSEcCtD
Rasagiline—Arthritis—Esomeprazole—Barrett's esophagus	0.00268	0.0047	CcSEcCtD
Rasagiline—Diplopia—Omeprazole—Barrett's esophagus	0.0026	0.00457	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Esomeprazole—Barrett's esophagus	0.0026	0.00457	CcSEcCtD
Rasagiline—Diplopia—Esomeprazole—Barrett's esophagus	0.0026	0.00457	CcSEcCtD
Rasagiline—Osteoarthritis—Omeprazole—Barrett's esophagus	0.0026	0.00457	CcSEcCtD
Rasagiline—Osteoarthritis—Esomeprazole—Barrett's esophagus	0.0026	0.00457	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Omeprazole—Barrett's esophagus	0.0026	0.00457	CcSEcCtD
Rasagiline—Migraine—Omeprazole—Barrett's esophagus	0.00256	0.00449	CcSEcCtD
Rasagiline—Migraine—Esomeprazole—Barrett's esophagus	0.00256	0.00449	CcSEcCtD
Rasagiline—Face oedema—Omeprazole—Barrett's esophagus	0.00251	0.00441	CcSEcCtD
Rasagiline—Face oedema—Esomeprazole—Barrett's esophagus	0.00251	0.00441	CcSEcCtD
Rasagiline—MAOB—digestive system—Barrett's esophagus	0.00247	0.097	CbGeAlD
Rasagiline—MAOB—Biological oxidations—CYP26A1—Barrett's esophagus	0.00236	0.026	CbGpPWpGaD
Rasagiline—Muscular weakness—Omeprazole—Barrett's esophagus	0.00229	0.00403	CcSEcCtD
Rasagiline—Muscular weakness—Esomeprazole—Barrett's esophagus	0.00229	0.00403	CcSEcCtD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—RELA—Barrett's esophagus	0.00228	0.0252	CbGpPWpGaD
Rasagiline—Dysphagia—Esomeprazole—Barrett's esophagus	0.00225	0.00395	CcSEcCtD
Rasagiline—Influenza—Esomeprazole—Barrett's esophagus	0.00225	0.00395	CcSEcCtD
Rasagiline—Asthma—Esomeprazole—Barrett's esophagus	0.00225	0.00395	CcSEcCtD
Rasagiline—Influenza—Omeprazole—Barrett's esophagus	0.00225	0.00395	CcSEcCtD
Rasagiline—Asthma—Omeprazole—Barrett's esophagus	0.00225	0.00395	CcSEcCtD
Rasagiline—Dysphagia—Omeprazole—Barrett's esophagus	0.00225	0.00395	CcSEcCtD
Rasagiline—Angina pectoris—Omeprazole—Barrett's esophagus	0.00219	0.00384	CcSEcCtD
Rasagiline—Angina pectoris—Esomeprazole—Barrett's esophagus	0.00219	0.00384	CcSEcCtD
Rasagiline—Dysuria—Esomeprazole—Barrett's esophagus	0.0021	0.00369	CcSEcCtD
Rasagiline—Dysuria—Omeprazole—Barrett's esophagus	0.0021	0.00369	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Omeprazole—Barrett's esophagus	0.00209	0.00367	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Esomeprazole—Barrett's esophagus	0.00209	0.00367	CcSEcCtD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—RELA—Barrett's esophagus	0.00208	0.023	CbGpPWpGaD
Rasagiline—Pollakiuria—Esomeprazole—Barrett's esophagus	0.00208	0.00365	CcSEcCtD
Rasagiline—Pollakiuria—Omeprazole—Barrett's esophagus	0.00208	0.00365	CcSEcCtD
Rasagiline—Erectile dysfunction—Esomeprazole—Barrett's esophagus	0.00207	0.00363	CcSEcCtD
Rasagiline—Erectile dysfunction—Omeprazole—Barrett's esophagus	0.00207	0.00363	CcSEcCtD
Rasagiline—BCL2—TP53 Network—TP53—Barrett's esophagus	0.00205	0.0227	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Esomeprazole—Barrett's esophagus	0.00205	0.0036	CcSEcCtD
Rasagiline—Photosensitivity reaction—Omeprazole—Barrett's esophagus	0.00205	0.0036	CcSEcCtD
Rasagiline—Weight decreased—Esomeprazole—Barrett's esophagus	0.00203	0.00357	CcSEcCtD
Rasagiline—Weight decreased—Omeprazole—Barrett's esophagus	0.00203	0.00357	CcSEcCtD
Rasagiline—Infestation—Omeprazole—Barrett's esophagus	0.002	0.00352	CcSEcCtD
Rasagiline—Infestation NOS—Esomeprazole—Barrett's esophagus	0.002	0.00352	CcSEcCtD
Rasagiline—Infestation—Esomeprazole—Barrett's esophagus	0.002	0.00352	CcSEcCtD
Rasagiline—Infestation NOS—Omeprazole—Barrett's esophagus	0.002	0.00352	CcSEcCtD
Rasagiline—Depression—Esomeprazole—Barrett's esophagus	0.002	0.00351	CcSEcCtD
Rasagiline—Depression—Omeprazole—Barrett's esophagus	0.002	0.00351	CcSEcCtD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—Barrett's esophagus	0.00199	0.022	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—Barrett's esophagus	0.00199	0.022	CbGpPWpGaD
Rasagiline—Stomatitis—Esomeprazole—Barrett's esophagus	0.00195	0.00343	CcSEcCtD
Rasagiline—Jaundice—Esomeprazole—Barrett's esophagus	0.00195	0.00343	CcSEcCtD
Rasagiline—Stomatitis—Omeprazole—Barrett's esophagus	0.00195	0.00343	CcSEcCtD
Rasagiline—Jaundice—Omeprazole—Barrett's esophagus	0.00195	0.00343	CcSEcCtD
Rasagiline—Conjunctivitis—Esomeprazole—Barrett's esophagus	0.00195	0.00342	CcSEcCtD
Rasagiline—Conjunctivitis—Omeprazole—Barrett's esophagus	0.00195	0.00342	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGES—Barrett's esophagus	0.00193	0.0213	CbGpPWpGaD
Rasagiline—Haematuria—Omeprazole—Barrett's esophagus	0.00191	0.00336	CcSEcCtD
Rasagiline—Haematuria—Esomeprazole—Barrett's esophagus	0.00191	0.00336	CcSEcCtD
Rasagiline—Epistaxis—Esomeprazole—Barrett's esophagus	0.00189	0.00332	CcSEcCtD
Rasagiline—Epistaxis—Omeprazole—Barrett's esophagus	0.00189	0.00332	CcSEcCtD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—RELA—Barrett's esophagus	0.00181	0.02	CbGpPWpGaD
Rasagiline—Rhinitis—Esomeprazole—Barrett's esophagus	0.0018	0.00317	CcSEcCtD
Rasagiline—Rhinitis—Omeprazole—Barrett's esophagus	0.0018	0.00317	CcSEcCtD
Rasagiline—Hypoaesthesia—Omeprazole—Barrett's esophagus	0.00179	0.00314	CcSEcCtD
Rasagiline—Hallucination—Esomeprazole—Barrett's esophagus	0.00179	0.00314	CcSEcCtD
Rasagiline—Hypoaesthesia—Esomeprazole—Barrett's esophagus	0.00179	0.00314	CcSEcCtD
Rasagiline—Hallucination—Omeprazole—Barrett's esophagus	0.00179	0.00314	CcSEcCtD
Rasagiline—Urinary tract disorder—Esomeprazole—Barrett's esophagus	0.00178	0.00312	CcSEcCtD
Rasagiline—Urinary tract disorder—Omeprazole—Barrett's esophagus	0.00178	0.00312	CcSEcCtD
Rasagiline—Oedema peripheral—Omeprazole—Barrett's esophagus	0.00177	0.00311	CcSEcCtD
Rasagiline—Oedema peripheral—Esomeprazole—Barrett's esophagus	0.00177	0.00311	CcSEcCtD
Rasagiline—Connective tissue disorder—Esomeprazole—Barrett's esophagus	0.00177	0.0031	CcSEcCtD
Rasagiline—Connective tissue disorder—Omeprazole—Barrett's esophagus	0.00177	0.0031	CcSEcCtD
Rasagiline—Urethral disorder—Omeprazole—Barrett's esophagus	0.00176	0.0031	CcSEcCtD
Rasagiline—Urethral disorder—Esomeprazole—Barrett's esophagus	0.00176	0.0031	CcSEcCtD
Rasagiline—CYP1A2—digestive system—Barrett's esophagus	0.00176	0.069	CbGeAlD
Rasagiline—BCL2—Ceramide signaling pathway—RELA—Barrett's esophagus	0.00169	0.0187	CbGpPWpGaD
Rasagiline—Eye disorder—Esomeprazole—Barrett's esophagus	0.00168	0.00295	CcSEcCtD
Rasagiline—Eye disorder—Omeprazole—Barrett's esophagus	0.00168	0.00295	CcSEcCtD
Rasagiline—BCL2—Activation of BH3-only proteins—TP53—Barrett's esophagus	0.00165	0.0182	CbGpPWpGaD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—RELA—Barrett's esophagus	0.00164	0.0181	CbGpPWpGaD
Rasagiline—Immune system disorder—Esomeprazole—Barrett's esophagus	0.00163	0.00285	CcSEcCtD
Rasagiline—Immune system disorder—Omeprazole—Barrett's esophagus	0.00163	0.00285	CcSEcCtD
Rasagiline—Mediastinal disorder—Esomeprazole—Barrett's esophagus	0.00162	0.00285	CcSEcCtD
Rasagiline—Mediastinal disorder—Omeprazole—Barrett's esophagus	0.00162	0.00285	CcSEcCtD
Rasagiline—Chills—Esomeprazole—Barrett's esophagus	0.00161	0.00283	CcSEcCtD
Rasagiline—Chills—Omeprazole—Barrett's esophagus	0.00161	0.00283	CcSEcCtD
Rasagiline—Alopecia—Esomeprazole—Barrett's esophagus	0.00159	0.00279	CcSEcCtD
Rasagiline—Alopecia—Omeprazole—Barrett's esophagus	0.00159	0.00279	CcSEcCtD
Rasagiline—Mental disorder—Esomeprazole—Barrett's esophagus	0.00158	0.00277	CcSEcCtD
Rasagiline—Mental disorder—Omeprazole—Barrett's esophagus	0.00158	0.00277	CcSEcCtD
Rasagiline—BCL2—IL-3 Signaling Pathway—CXCL8—Barrett's esophagus	0.00157	0.0173	CbGpPWpGaD
Rasagiline—Malnutrition—Omeprazole—Barrett's esophagus	0.00157	0.00275	CcSEcCtD
Rasagiline—Malnutrition—Esomeprazole—Barrett's esophagus	0.00157	0.00275	CcSEcCtD
Rasagiline—Flatulence—Esomeprazole—Barrett's esophagus	0.00154	0.00271	CcSEcCtD
Rasagiline—Flatulence—Omeprazole—Barrett's esophagus	0.00154	0.00271	CcSEcCtD
Rasagiline—Dysgeusia—Omeprazole—Barrett's esophagus	0.00153	0.00269	CcSEcCtD
Rasagiline—Dysgeusia—Esomeprazole—Barrett's esophagus	0.00153	0.00269	CcSEcCtD
Rasagiline—Back pain—Omeprazole—Barrett's esophagus	0.00152	0.00266	CcSEcCtD
Rasagiline—Back pain—Esomeprazole—Barrett's esophagus	0.00152	0.00266	CcSEcCtD
Rasagiline—Muscle spasms—Esomeprazole—Barrett's esophagus	0.00151	0.00264	CcSEcCtD
Rasagiline—Muscle spasms—Omeprazole—Barrett's esophagus	0.00151	0.00264	CcSEcCtD
Rasagiline—Tremor—Omeprazole—Barrett's esophagus	0.00147	0.00258	CcSEcCtD
Rasagiline—Tremor—Esomeprazole—Barrett's esophagus	0.00147	0.00258	CcSEcCtD
Rasagiline—Ill-defined disorder—Omeprazole—Barrett's esophagus	0.00145	0.00255	CcSEcCtD
Rasagiline—Ill-defined disorder—Esomeprazole—Barrett's esophagus	0.00145	0.00255	CcSEcCtD
Rasagiline—Anaemia—Omeprazole—Barrett's esophagus	0.00145	0.00254	CcSEcCtD
Rasagiline—Anaemia—Esomeprazole—Barrett's esophagus	0.00145	0.00254	CcSEcCtD
Rasagiline—Agitation—Esomeprazole—Barrett's esophagus	0.00144	0.00253	CcSEcCtD
Rasagiline—Agitation—Omeprazole—Barrett's esophagus	0.00144	0.00253	CcSEcCtD
Rasagiline—Malaise—Esomeprazole—Barrett's esophagus	0.00141	0.00248	CcSEcCtD
Rasagiline—Malaise—Omeprazole—Barrett's esophagus	0.00141	0.00248	CcSEcCtD
Rasagiline—Vertigo—Omeprazole—Barrett's esophagus	0.00141	0.00247	CcSEcCtD
Rasagiline—Vertigo—Esomeprazole—Barrett's esophagus	0.00141	0.00247	CcSEcCtD
Rasagiline—Leukopenia—Omeprazole—Barrett's esophagus	0.0014	0.00246	CcSEcCtD
Rasagiline—Leukopenia—Esomeprazole—Barrett's esophagus	0.0014	0.00246	CcSEcCtD
Rasagiline—Cough—Esomeprazole—Barrett's esophagus	0.00137	0.0024	CcSEcCtD
Rasagiline—Cough—Omeprazole—Barrett's esophagus	0.00137	0.0024	CcSEcCtD
Rasagiline—BCL2—ATF-2 transcription factor network—CXCL8—Barrett's esophagus	0.00135	0.0149	CbGpPWpGaD
Rasagiline—Hypertension—Esomeprazole—Barrett's esophagus	0.00135	0.00237	CcSEcCtD
Rasagiline—Hypertension—Omeprazole—Barrett's esophagus	0.00135	0.00237	CcSEcCtD
Rasagiline—Chest pain—Esomeprazole—Barrett's esophagus	0.00133	0.00234	CcSEcCtD
Rasagiline—Arthralgia—Esomeprazole—Barrett's esophagus	0.00133	0.00234	CcSEcCtD
Rasagiline—Chest pain—Omeprazole—Barrett's esophagus	0.00133	0.00234	CcSEcCtD
Rasagiline—Arthralgia—Omeprazole—Barrett's esophagus	0.00133	0.00234	CcSEcCtD
Rasagiline—Anxiety—Esomeprazole—Barrett's esophagus	0.00133	0.00233	CcSEcCtD
Rasagiline—Anxiety—Omeprazole—Barrett's esophagus	0.00133	0.00233	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Omeprazole—Barrett's esophagus	0.00132	0.00232	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Esomeprazole—Barrett's esophagus	0.00132	0.00232	CcSEcCtD
Rasagiline—Discomfort—Omeprazole—Barrett's esophagus	0.00132	0.00231	CcSEcCtD
Rasagiline—Discomfort—Esomeprazole—Barrett's esophagus	0.00132	0.00231	CcSEcCtD
Rasagiline—Dry mouth—Esomeprazole—Barrett's esophagus	0.0013	0.00229	CcSEcCtD
Rasagiline—Dry mouth—Omeprazole—Barrett's esophagus	0.0013	0.00229	CcSEcCtD
Rasagiline—Confusional state—Omeprazole—Barrett's esophagus	0.00129	0.00226	CcSEcCtD
Rasagiline—Confusional state—Esomeprazole—Barrett's esophagus	0.00129	0.00226	CcSEcCtD
Rasagiline—Infection—Omeprazole—Barrett's esophagus	0.00127	0.00223	CcSEcCtD
Rasagiline—Infection—Esomeprazole—Barrett's esophagus	0.00127	0.00223	CcSEcCtD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP26A1—Barrett's esophagus	0.00127	0.014	CbGpPWpGaD
Rasagiline—Shock—Omeprazole—Barrett's esophagus	0.00126	0.00221	CcSEcCtD
Rasagiline—Shock—Esomeprazole—Barrett's esophagus	0.00126	0.00221	CcSEcCtD
Rasagiline—Nervous system disorder—Omeprazole—Barrett's esophagus	0.00125	0.0022	CcSEcCtD
Rasagiline—Nervous system disorder—Esomeprazole—Barrett's esophagus	0.00125	0.0022	CcSEcCtD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP26A1—Barrett's esophagus	0.00125	0.0138	CbGpPWpGaD
Rasagiline—Skin disorder—Omeprazole—Barrett's esophagus	0.00124	0.00218	CcSEcCtD
Rasagiline—Skin disorder—Esomeprazole—Barrett's esophagus	0.00124	0.00218	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—HGF—Barrett's esophagus	0.00124	0.0137	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Esomeprazole—Barrett's esophagus	0.00124	0.00217	CcSEcCtD
Rasagiline—Hyperhidrosis—Omeprazole—Barrett's esophagus	0.00124	0.00217	CcSEcCtD
Rasagiline—Anorexia—Esomeprazole—Barrett's esophagus	0.00122	0.00214	CcSEcCtD
Rasagiline—Anorexia—Omeprazole—Barrett's esophagus	0.00122	0.00214	CcSEcCtD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—Barrett's esophagus	0.00118	0.013	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—Barrett's esophagus	0.00118	0.013	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Esomeprazole—Barrett's esophagus	0.00116	0.00204	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Omeprazole—Barrett's esophagus	0.00116	0.00204	CcSEcCtD
Rasagiline—Insomnia—Omeprazole—Barrett's esophagus	0.00116	0.00203	CcSEcCtD
Rasagiline—Insomnia—Esomeprazole—Barrett's esophagus	0.00116	0.00203	CcSEcCtD
Rasagiline—Paraesthesia—Esomeprazole—Barrett's esophagus	0.00115	0.00202	CcSEcCtD
Rasagiline—Paraesthesia—Omeprazole—Barrett's esophagus	0.00115	0.00202	CcSEcCtD
Rasagiline—Dyspnoea—Esomeprazole—Barrett's esophagus	0.00114	0.002	CcSEcCtD
Rasagiline—Dyspnoea—Omeprazole—Barrett's esophagus	0.00114	0.002	CcSEcCtD
Rasagiline—Somnolence—Esomeprazole—Barrett's esophagus	0.00114	0.002	CcSEcCtD
Rasagiline—Somnolence—Omeprazole—Barrett's esophagus	0.00114	0.002	CcSEcCtD
Rasagiline—Dyspepsia—Omeprazole—Barrett's esophagus	0.00113	0.00198	CcSEcCtD
Rasagiline—Dyspepsia—Esomeprazole—Barrett's esophagus	0.00113	0.00198	CcSEcCtD
Rasagiline—BCL2—Apoptosis—CDKN2A—Barrett's esophagus	0.00112	0.0124	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN2A—Barrett's esophagus	0.00112	0.0124	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—APC—Barrett's esophagus	0.00112	0.0124	CbGpPWpGaD
Rasagiline—Decreased appetite—Esomeprazole—Barrett's esophagus	0.00111	0.00195	CcSEcCtD
Rasagiline—Decreased appetite—Omeprazole—Barrett's esophagus	0.00111	0.00195	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Omeprazole—Barrett's esophagus	0.0011	0.00194	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Esomeprazole—Barrett's esophagus	0.0011	0.00194	CcSEcCtD
Rasagiline—Constipation—Esomeprazole—Barrett's esophagus	0.00109	0.00192	CcSEcCtD
Rasagiline—Constipation—Omeprazole—Barrett's esophagus	0.00109	0.00192	CcSEcCtD
Rasagiline—BCL2—Apoptosis—RELA—Barrett's esophagus	0.00108	0.0119	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CDKN2A—Barrett's esophagus	0.00105	0.0116	CbGpPWpGaD
Rasagiline—Feeling abnormal—Omeprazole—Barrett's esophagus	0.00105	0.00185	CcSEcCtD
Rasagiline—Feeling abnormal—Esomeprazole—Barrett's esophagus	0.00105	0.00185	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—PTGS2—Barrett's esophagus	0.00105	0.0116	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—Barrett's esophagus	0.00105	0.0116	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Esomeprazole—Barrett's esophagus	0.00105	0.00184	CcSEcCtD
Rasagiline—Gastrointestinal pain—Omeprazole—Barrett's esophagus	0.00105	0.00184	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP26A1—Barrett's esophagus	0.00103	0.0113	CbGpPWpGaD
Rasagiline—Urticaria—Omeprazole—Barrett's esophagus	0.00102	0.00178	CcSEcCtD
Rasagiline—Urticaria—Esomeprazole—Barrett's esophagus	0.00102	0.00178	CcSEcCtD
Rasagiline—Abdominal pain—Esomeprazole—Barrett's esophagus	0.00101	0.00177	CcSEcCtD
Rasagiline—Body temperature increased—Esomeprazole—Barrett's esophagus	0.00101	0.00177	CcSEcCtD
Rasagiline—Abdominal pain—Omeprazole—Barrett's esophagus	0.00101	0.00177	CcSEcCtD
Rasagiline—Body temperature increased—Omeprazole—Barrett's esophagus	0.00101	0.00177	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—RELA—Barrett's esophagus	0.00101	0.0111	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—HGF—Barrett's esophagus	0.000971	0.0107	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CXCL8—Barrett's esophagus	0.000948	0.0105	CbGpPWpGaD
Rasagiline—Hypersensitivity—Omeprazole—Barrett's esophagus	0.000942	0.00165	CcSEcCtD
Rasagiline—Hypersensitivity—Esomeprazole—Barrett's esophagus	0.000942	0.00165	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN2A—Barrett's esophagus	0.000941	0.0104	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—APC—Barrett's esophagus	0.00092	0.0102	CbGpPWpGaD
Rasagiline—Asthenia—Esomeprazole—Barrett's esophagus	0.000917	0.00161	CcSEcCtD
Rasagiline—Asthenia—Omeprazole—Barrett's esophagus	0.000917	0.00161	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—Barrett's esophagus	0.000913	0.0101	CbGpPWpGaD
Rasagiline—Pruritus—Omeprazole—Barrett's esophagus	0.000905	0.00159	CcSEcCtD
Rasagiline—Pruritus—Esomeprazole—Barrett's esophagus	0.000905	0.00159	CcSEcCtD
Rasagiline—Diarrhoea—Omeprazole—Barrett's esophagus	0.000875	0.00154	CcSEcCtD
Rasagiline—Diarrhoea—Esomeprazole—Barrett's esophagus	0.000875	0.00154	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CXCL8—Barrett's esophagus	0.000853	0.00941	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—APC—Barrett's esophagus	0.000848	0.00936	CbGpPWpGaD
Rasagiline—Dizziness—Esomeprazole—Barrett's esophagus	0.000845	0.00148	CcSEcCtD
Rasagiline—Dizziness—Omeprazole—Barrett's esophagus	0.000845	0.00148	CcSEcCtD
Rasagiline—Vomiting—Omeprazole—Barrett's esophagus	0.000813	0.00143	CcSEcCtD
Rasagiline—Vomiting—Esomeprazole—Barrett's esophagus	0.000813	0.00143	CcSEcCtD
Rasagiline—Rash—Esomeprazole—Barrett's esophagus	0.000806	0.00142	CcSEcCtD
Rasagiline—Rash—Omeprazole—Barrett's esophagus	0.000806	0.00142	CcSEcCtD
Rasagiline—Dermatitis—Esomeprazole—Barrett's esophagus	0.000805	0.00141	CcSEcCtD
Rasagiline—Dermatitis—Omeprazole—Barrett's esophagus	0.000805	0.00141	CcSEcCtD
Rasagiline—Headache—Omeprazole—Barrett's esophagus	0.000801	0.00141	CcSEcCtD
Rasagiline—Headache—Esomeprazole—Barrett's esophagus	0.000801	0.00141	CcSEcCtD
Rasagiline—Nausea—Omeprazole—Barrett's esophagus	0.000759	0.00133	CcSEcCtD
Rasagiline—Nausea—Esomeprazole—Barrett's esophagus	0.000759	0.00133	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—APC—Barrett's esophagus	0.000718	0.00792	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—Barrett's esophagus	0.000656	0.00724	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—Barrett's esophagus	0.000626	0.0069	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—Barrett's esophagus	0.000587	0.00647	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP26A1—Barrett's esophagus	0.000545	0.00602	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—Barrett's esophagus	0.000545	0.00601	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP26A1—Barrett's esophagus	0.000538	0.00593	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGES—Barrett's esophagus	0.000532	0.00587	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—Barrett's esophagus	0.000523	0.00577	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—Barrett's esophagus	0.000508	0.0056	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RELA—Barrett's esophagus	0.000417	0.0046	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TP53—Barrett's esophagus	0.000416	0.00459	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Barrett's esophagus	0.000405	0.00447	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP26A1—Barrett's esophagus	0.000403	0.00445	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—Barrett's esophagus	0.000391	0.00432	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—Barrett's esophagus	0.000383	0.00423	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—Barrett's esophagus	0.000379	0.00418	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—Barrett's esophagus	0.000324	0.00358	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC9A1—Barrett's esophagus	0.00029	0.0032	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGES—Barrett's esophagus	0.000276	0.00305	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HGF—Barrett's esophagus	0.000232	0.00256	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RELA—Barrett's esophagus	0.000232	0.00255	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RELA—Barrett's esophagus	0.000135	0.00149	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARG—Barrett's esophagus	0.000133	0.00146	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGES—Barrett's esophagus	0.000123	0.00136	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—Barrett's esophagus	0.000104	0.00115	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP26A1—Barrett's esophagus	9.33e-05	0.00103	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—Barrett's esophagus	6.89e-05	0.00076	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC9A1—Barrett's esophagus	6.72e-05	0.000742	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Barrett's esophagus	5.42e-05	0.000598	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARG—Barrett's esophagus	3.07e-05	0.000339	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—Barrett's esophagus	2.41e-05	0.000266	CbGpPWpGaD
